Vestmark Advisory Solutions Inc. Buys Shares of 1,935 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vestmark Advisory Solutions Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,935 shares of the biopharmaceutical company’s stock, valued at approximately $1,699,000.

A number of other institutional investors and hedge funds have also modified their holdings of REGN. FMR LLC increased its stake in Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares in the last quarter. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares in the last quarter. abrdn plc increased its stake in Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Regeneron Pharmaceuticals by 129.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after buying an additional 122,103 shares during the last quarter. Finally, TD Asset Management Inc grew its holdings in shares of Regeneron Pharmaceuticals by 64.4% in the 3rd quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock valued at $148,353,000 after acquiring an additional 70,628 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Joseph J. Larosa sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total transaction of $950,000.00. Following the completion of the transaction, the executive vice president now owns 38,543 shares of the company’s stock, valued at $36,615,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Joseph J. Larosa sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total transaction of $950,000.00. Following the transaction, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at approximately $36,615,850. The disclosure for this sale can be found here. Insiders sold 10,095 shares of company stock valued at $9,664,476 over the last quarter. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $19.39 during trading hours on Friday, hitting $957.00. The company’s stock had a trading volume of 547,373 shares, compared to its average volume of 509,442. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 6.40 and a quick ratio of 4.94. The stock has a fifty day simple moving average of $943.75 and a 200-day simple moving average of $896.33. The company has a market capitalization of $105.04 billion, a P/E ratio of 28.27, a PEG ratio of 2.74 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Regeneron Pharmaceuticals’s revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $10.96 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on REGN shares. TD Cowen upped their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.77.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.